Mostrar el registro sencillo del ítem

Artículo

dc.creatorMartín Banderas, Lucía 
dc.creatorÁlvarez Fuentes, Josefa 
dc.creatorDurán Lobato, María Matilde 
dc.creatorPrados Salazar, José Carlos 
dc.creatorMelguizo Alonso, Consolación 
dc.creatorFernández Arévalo, María Mercedes 
dc.creatorHolgado Villafuerte, María Ángeles 
dc.date.accessioned2015-02-26T19:11:30Z
dc.date.available2015-02-26T19:11:30Z
dc.date.issued2012
dc.identifier.issn1176-9114es
dc.identifier.issn1178-2013es
dc.identifier.urihttp://hdl.handle.net/11441/22786
dc.description.abstractCB13 (1-Naphthalenyl[4-(pentyloxy)-1-naphthalenyl]methanone)-loaded poly(lactic-co-glycolic acid) nanoparticles (NPs) were produced by nanoprecipitation and tested for their in vitro release behavior and in vitro cytotoxicity assays. The effects of several formulation parameters such as polymer type, surfactant concentration, and initial drug amount were studied. NPs had a particle size 90–300 nm in diameter. Results obtained show that the main influence on particle size was the type of polymer employed during the particle production: the greater the hydrophobicity, the smaller the particle size. In terms of encapsulation efficiency (%), high values were achieved (∼68%–90%) for all formulations prepared due to the poor solubility of CB13 in the external aqueous phase. Moreover, an inverse relationship between release rate and NP size was found. On the other hand, low molecular weight and low lactide content resulted in a less hydrophobic polymer with increased rates of water absorption, hydrolysis, and erosion. NPs showed no cytotoxicity and may be considered to be appropriate for drug-delivery purposes.es
dc.formatapplication/pdfes
dc.language.isoenges
dc.relation.ispartofInternational Journal of Nanomedicine, 7, 5793–5806es
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectNeuropathic paines
dc.subjectCB13es
dc.subjectnanoprecipitationes
dc.titleCannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studieses
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Farmacia y Tecnología Farmacéuticaes
dc.relation.publisherversion10.2147/IJN.S34633es
dc.identifier.idushttps://idus.us.es/xmlui/handle/11441/22786

FicherosTamañoFormatoVerDescripción
Cannabinoid derivate loaded PLGA ...2.448MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional